Bellevue Life Sciences Acquisition Corp.

Status: Live Deal
U=S+W+R W=S@11.5 R=S/10
IPO Proceeds, $M $69.00M
IPO Date Feb 10, 2023
CEO Kuk Hyoun Hwang
Left Lead Chardan
IPO Cash in Trust 101.8%
SPAC Tenor 9 + 6
IPO Sector Healthcare

Healthcare industry, more specifically in the biotechnology sector

IPO Geography Global
Target Company OSR Holdings
Deal Announced Nov 16, 2023
Deal Size, $M TBD
Deal Sector Healthcare
Deal Geography Global
SEC Filings www.sec.gov
Approval Vote TBD
Amendment Vote May 10, 2024
BLAC BLACU BLACW BLACR

Sign up for Free Trial

No credit card required

Sign in for more on Bellevue Life Sciences Acquisition Corp.:

  • Structure and cap table
  • 7 directors & officers
  • 19 filings and events
  • 2 underwriters
Structure

Sign in to view structure, cap table, and calendar of events.

Team
Name Age Title
Kuk Hyoun Hwang 47 CEO and Director
David J. Yoo 49 CFO
Jun Chul Whang 58 Director
Steven Reed 72 Director and Chairman
Rad Roberts 54 Director
In Chul Chung 59 Director
Jin Whan Park 55 Director

Sign in to view team biographies and more sponsor and affiliate data.

Advisors
Underwriters
Chardan BR 5,950,000 units
B. Riley FBR 50,000
6,000,000 units
Up-Front UW fee 2.00 %
Deferred UW fee 3.00 %

Sign in to view more advisor data.

Filings

Sign in to view 19 filings.

Shareholders

Sign in to view shareholders 13F filing data.